Raghav Garg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Raghav Garg has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Rajesh Kumar Soni
Department of General Surgery, VMMC & Safdarjung Hospital, New Delhi, India
3 shared publicationsKashinath Singh
Department of General Surgery, VMMC & Safdarjung Hospital, New Delhi, India
2 shared publicationsRatnakar Namdeo
Department of General Surgery, VMMC and SJH, New Delhi, India
2 shared publications- Arun Kumar
Department of Surgical disciplines All India Institute of Medical Sciences New Delhi India
1 shared publication Basudev Kumar Jha
VMMC & SJH
1 shared publicationHimani Aneja
VMMC & SJH
1 shared publication
Latest Publications
- 16 April 2026
- Published by Wiley in World Journal of Surgery
- Vol. 50 (6) , 1493-1500
A Double‐Blind Randomised Controlled Trial Comparing the Efficacy of Nifedipine and Diltiazem Ointments in the Treatment of Anal Fissure
Background: Anal fissure, a common anorectal disorder, usually presents with pain, bleeding, and itching during or after defecation. These fissures can be classified as acute, chronic, or acute on chronic, depending on the duration of symptoms (6 weeks or less for acute and more than 6 weeks for chronic). Traditional treatment involves medical interventions to reduce sphincter tone and improve blood flow. Topical calcium channel blockers (CCBs) have shown promising results in conservative management. This study aimed to compare the efficacy and safety of Nifedipine versus Diltiazem ointments in treating anal fissures through a double‐blind, randomized controlled trial conducted at a tertiary care centre. Methods: From August 2022 to November 2023, 110 patients with acute, chronic, or acute‐on‐chronic anal fissures were randomized into two groups, receiving 1 g of either 0.3% Nifedipine and 2% lidocaine or 2% Diltiazem and 2% lidocaine ointments twice daily for 6 weeks. The primary outcome was assessed using the REALISE score, which measures pain, bleeding, and overall quality of life. Secondary outcomes included perianal irritation and adverse events. Results: Both treatments significantly improved the REALISE scores, with reductions from baseline to 6 weeks indicating effective symptom relief. Nifedipine reduced the score from 17.7 ± 3.9 to 5.3 ± 1.8 ( p = 0.0001), while Diltiazem reduced it from 16.3 ± 3.9 to 5.8 ± 2.3 ( p = 0.0001). Healing rates were comparable between groups (70.9% for Nifedipine and 67.3% for Diltiazem), and both treatments were well‐tolerated with minimal side effects. Conclusion: This study confirms that both Nifedipine and Diltiazem are effective first‐line treatments for anal fissures, offering viable short‐term non‐surgical options. Further research with longer follow‐up and multicentric studies is needed to evaluate long‐term outcomes and treatment combinations. Trial Registration: This study was registered in the Indian Clinical Trials Registry under the code: CTRI/2022/04/042081. Registered on April 22, 2022 (URL: https://ctri.nic.in/Clinicaltrials/rmaindet.php?trialid=66601&EncHid=71722.40664&modid=1&compid=19 )
- 16 April 2026
- Published by Wiley in World Journal of Surgery
- Vol. 50 (6) , 1493-1500
A Double‐Blind Randomised Controlled Trial Comparing the Efficacy of Nifedipine and Diltiazem Ointments in the Treatment of Anal Fissure
Background: Anal fissure, a common anorectal disorder, usually presents with pain, bleeding, and itching during or after defecation. These fissures can be classified as acute, chronic, or acute on chronic, depending on the duration of symptoms (6 weeks or less for acute and more than 6 weeks for chronic). Traditional treatment involves medical interventions to reduce sphincter tone and improve blood flow. Topical calcium channel blockers (CCBs) have shown promising results in conservative management. This study aimed to compare the efficacy and safety of Nifedipine versus Diltiazem ointments in treating anal fissures through a double‐blind, randomized controlled trial conducted at a tertiary care centre. Methods: From August 2022 to November 2023, 110 patients with acute, chronic, or acute‐on‐chronic anal fissures were randomized into two groups, receiving 1 g of either 0.3% Nifedipine and 2% lidocaine or 2% Diltiazem and 2% lidocaine ointments twice daily for 6 weeks. The primary outcome was assessed using the REALISE score, which measures pain, bleeding, and overall quality of life. Secondary outcomes included perianal irritation and adverse events. Results: Both treatments significantly improved the REALISE scores, with reductions from baseline to 6 weeks indicating effective symptom relief. Nifedipine reduced the score from 17.7 ± 3.9 to 5.3 ± 1.8 ( p = 0.0001), while Diltiazem reduced it from 16.3 ± 3.9 to 5.8 ± 2.3 ( p = 0.0001). Healing rates were comparable between groups (70.9% for Nifedipine and 67.3% for Diltiazem), and both treatments were well‐tolerated with minimal side effects. Conclusion: This study confirms that both Nifedipine and Diltiazem are effective first‐line treatments for anal fissures, offering viable short‐term non‐surgical options. Further research with longer follow‐up and multicentric studies is needed to evaluate long‐term outcomes and treatment combinations. Trial Registration: This study was registered in the Indian Clinical Trials Registry under the code: CTRI/2022/04/042081. Registered on April 22, 2022 (URL: https://ctri.nic.in/Clinicaltrials/rmaindet.php?trialid=66601&EncHid=71722.40664&modid=1&compid=19 )
- Open Access
- 3 March 2020
- Published by Springer Nature in Indian Journal of Surgery
- Vol. 86 (S2) , 492
Hernia Uteri Inguinale
- 3 March 2020
- Published by Springer Nature in Indian Journal of Surgery
- Vol. 86 (S2) , 492
Open AccessHernia Uteri Inguinale
- Open Access
- 25 September 2018
- Published by Medip Academy in International Surgery Journal
- Vol. 5 (10) , 3394-3398
Correlation of the laboratory risk indicators for necrotizing fasciitis (LRINEC) score with the clinical features and surgical management of necrotizing soft tissue infections
Background: Necrotizing fasciitis (NF) is a devastating soft tissue infection associated with potentially poor outcomes. The Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC) score has been introduced as a diagnostic tool for NF. We aimed to correlate the clinical features of NSTI with the LRINEC score, its application to distinguish Necrotizing Fasciitis (NF) from other non NSTI and its utility in early surgical management of NSTI.Methods: Patients were evaluated for various symptoms and signs at the time of admission and certain laboratory parameters were assessed. LRINEC score was then calculated. Correlation of the management and severity of infections with respective LRINEC score was then found out.Results: LRINEC score for predicting conservative management of NSTI has a sensitivity of 81.8% and specificity of 98% while for predicting amputation and mortality shows a sensitivity of 100% and specificity of 84.5%.Conclusions: The LRINEC score is a robust score capable of detecting even clinically early cases of necrotizing fasciitis.
- 25 September 2018
- Published by Medip Academy in International Surgery Journal
- Vol. 5 (10) , 3394-3398
Open AccessCorrelation of the laboratory risk indicators for necrotizing fasciitis (LRINEC) score with the clinical features and surgical management of necrotizing soft tissue infections
Background: Necrotizing fasciitis (NF) is a devastating soft tissue infection associated with potentially poor outcomes. The Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC) score has been introduced as a diagnostic tool for NF. We aimed to correlate the clinical features of NSTI with the LRINEC score, its application to distinguish Necrotizing Fasciitis (NF) from other non NSTI and its utility in early surgical management of NSTI.Methods: Patients were evaluated for various symptoms and signs at the time of admission and certain laboratory parameters were assessed. LRINEC score was then calculated. Correlation of the management and severity of infections with respective LRINEC score was then found out.Results: LRINEC score for predicting conservative management of NSTI has a sensitivity of 81.8% and specificity of 98% while for predicting amputation and mortality shows a sensitivity of 100% and specificity of 84.5%.Conclusions: The LRINEC score is a robust score capable of detecting even clinically early cases of necrotizing fasciitis.
- 11 September 2018
- Published by Springer Nature in Indian Journal of Surgery
- Vol. 81 (2) , 192-194
Hernia Uteri Inguinale: a Travesty of Nature
- 11 September 2018
- Published by Springer Nature in Indian Journal of Surgery
- Vol. 81 (2) , 192-194
Hernia Uteri Inguinale: a Travesty of Nature
- Open Access
- 1 January 2018
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 53, 277-280
Primary pelvic hydatid cyst: A rare case presenting with obstructive uropathy
Hydatid disease is caused by infection with larva of the cestode echinococcus. Humans are accidental intermediate hosts. Primary pelvic hydatid cyst is a rare entity. This is a case report of a 50 year old gentleman who presented to us as a case of suprapubic swelling and difficulty in micturition. General physical examination and radiological evaluation confirmed a multiloculated pelvic swelling. Patient was subjected to laparotomy which confirmed the diagnosis of a primary pelvic hydatid disease. Surgery is the optimal treatment of the pelvic hydatid disease. Radical resectional procedure or en bloc resection that removes the entire pericyst is the surgical technique of choice. Familiarity with atypical manifestations of hydatid disease may be helpful in making a prompt and accurate diagnosis. Surgery is the treatment of choice.
- 1 January 2018
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 53, 277-280
Open AccessPrimary pelvic hydatid cyst: A rare case presenting with obstructive uropathy
Hydatid disease is caused by infection with larva of the cestode echinococcus. Humans are accidental intermediate hosts. Primary pelvic hydatid cyst is a rare entity. This is a case report of a 50 year old gentleman who presented to us as a case of suprapubic swelling and difficulty in micturition. General physical examination and radiological evaluation confirmed a multiloculated pelvic swelling. Patient was subjected to laparotomy which confirmed the diagnosis of a primary pelvic hydatid disease. Surgery is the optimal treatment of the pelvic hydatid disease. Radical resectional procedure or en bloc resection that removes the entire pericyst is the surgical technique of choice. Familiarity with atypical manifestations of hydatid disease may be helpful in making a prompt and accurate diagnosis. Surgery is the treatment of choice.